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Background
Cell-culture based vaccines are a valuable alternative to
egg-produced vaccines. The equivalent of 1500 influenza
vaccine doses can be produced in a 1L bioreactor within
48 hours with HEK293 cells. The kinetics of production
of H1N1 A/Puerto Rico/8/68 in HEK293 cells has been
previously characterized by our group [1]; higher viral
production is achieved when cells are infected at a mul-
tiplicity of infection (MOI) of 0.01 compared to an MOI
of 1. Also, two cycles of infection take place: a first
round of virus is produced at 8 hours post-infection
(hpi) which then infect cells again and lead to a second
viral exit at 16 hpi.
Infection triggers a cascade of intracellular responses
which contributes to viral replication, but eventually
leads to cell death. Most studies focus on one pathway
at a time, and aim at limiting the extent of the infection
through the use of inhibitors. Our goal however is to
increase viral yield and quality. The main objective is
therefore to understand and manipulate the molecular
events taking place at the cellular level upon influenza
infection and replication, with particular attention to
key time points corresponding to viral production and
exit. Signaling pathways examined include the Akt,
mTOR and ERK pathway, and their activation levels
were determined by measuring their phosphorylation
states.
Materials and methods
HEK293 cells were grown in suspension in serum free
media (SFM4Transfx-293, HyClone). Cells at a density
of 2E06 cells/ml were infected at an MOI of 0.01, in the
presence of 1 μg/ml trypsin-TPCK, with H1N1 A/Puerto
Rico/8 (H1N1 PR/8) or H3N2 A/Aichi/8/68 (H3N2
Aichi). Non-infected cells, but treated with trypsin-
TPCK were used as a negative control. Samples were
collected at 0.5 to 42 hpi, fixed with 2% paraformalde-
hyde, permeabilized and stored in methanol at -80oC
until analysis. Phospho-specific antibodies (Cell Signal-
ing) were used to measure phospho-Akt (S473), phos-
pho-mTOR (S2448) and phospho-Erk (Thr202-Tyr204)
using flow cytometry. The presence of influenza virus
was simultaneously assessed by staining hemagglutinin
(HA), the main surface protein of influenza. Cell viabi-
lity was monitored throughout the infection period with
an automated cell counter (Cedex HiRes, Roche). Viral
production was quantified by measuring HA concentra-
tion using the dot-blot technique and an anti-HA anti-
body developed in house. The infectious titer was
determined by TCID50 in MDCK cells.
Results
Cell viability remained above 97% during the first 24 hpi,
and declined to less than 50% by 42hpi. Influenza infec-
tion with H1N1 PR/8 highly activated Akt with an
18-fold increase in phosphorylation at 24hpi. H3N2 Aichi
also activated Akt but to a lesser extent with a 6-fold
increase in phosphorylation at 24hpi (Figure 1A). These
results suggest that signaling pathways are differentially
modulated depending on the strain of influenza virus.
Akt was reported to be activated during viral replication
in order to prevent premature apoptosis [2-6]; the viral
Non-Structural Protein 1 (NS1) activates the Akt path-
way in the late stages of infection which inhibits Caspase-
9 and results in anti-apoptotic signaling. NS-1 is strain
specific and could explain why Akt is more highly acti-
vated by H1N1 PR/8 than by H3N2 Aichi.
In parallel, the phosphorylation of mTOR was
increased during the first 24hpi but remained stable, and
was similar for the two strains of influenza examined
* Correspondence: Sven.Ansorge@nrc-cnrc.gc.ca
1Vaccine Program, Human Health Therapeutics, National Research Council,
Montréal, Québec, H4P 2R2, Canada
Full list of author information is available at the end of the article
Manceur et al. BMC Proceedings 2015, 9(Suppl 9):P9
http://www.biomedcentral.com/1753-6561/9/S9/P9
© 2015 Manceur et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
(Figure 1B). Finally, ERK was initially activated by infection
with H3N2 Aichi but not with H1N1 PR/8, and decreased
at 24hpi with both strains (Figure 1C).The profile of acti-
vation of each kinase reflects different cellular events
caused by viral infection: mTOR is solicited during protein
synthesis while Erk is involved in export of viral ribonu-
cleoproteins from the nucleus to the cytoplasm [7-9].
Next, in order to increase viral yield, we first focused
on modulating Akt in cells infected with H1N1 PR/8.
Based on the profile of activation of Akt, small mole-
cules were added to either inhibit or activate Akt at
time of infection (T.O.I) which corresponds to viral
entry, or 15 to 17hpi which coincides with viral exit.
Viral yield was measured by quantifying the total
amount of HA, the main surface protein produced by
influenza viruses, and by evaluating the infectious titer
in a TCID50 assay. Conditions in which Akt is inhibited
at T.O.I. or activated at 17hpi, resulted in a significant
increase in HA concentrations by 2 fold and in infec-
tious viral titer by 1 log (Table 1). In contrast, inhibiting
Akt at a later time in the infection process, or activating
Akt at T.O.I. did not improve viral yield (Table 1). This
finding highlights the importance of considering the
kinetics of activation of molecular switches when
designing feeding strategies.
Conclusions
We have systematically investigated multiple signaling
pathways using flow cytometry, with particular attention
to time points corresponding to viral entry and exit. An
understanding of the timing of these events will facilitate
the selection of small molecules to control signaling
pathways and we have first evidence that this will lead to
an improved feeding strategy. As a proof of principle, we
show that modulation at Akt at strategic time points sig-
nificantly increases viral yield. Other important signaling
molecules that will be examined include PKC, NFkB and
P53. Based on the data thus obtained, a cocktail of small
molecules can be prepared and added to the culture at
the most appropriate time in order to improve the yield
and the quality of the virus generated for vaccine
production.
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Figure 1 Profiles of activation of phospho-Akt (A), phospho-mTOR (B) and phospho-ERK (C). The phosphorylation state of each kinase
was detected with a phospho-specific FITC-labelled antibody. Results are presented as fold difference compared to the non-infected control.
Average ± SD (n = 2). The dashed line represents no change in the infected samples compared to control (a fold change of 1). Legend: H1N1
PR8 is shown in red, and H3N2 Aichi is shown in blue.
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